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1 |  INTRODUCTION
Chronic respiratory failure (CRF) can result from various 
underlying diseases such as chronic obstructive pulmonary 
disease (COPD), obesity hypoventilation syndrome (OHS), 
restrictive thoracic wall disease (RTWD) or neuromuscular 
disease (NMD).1 All of these severe, often incurable diseases 
can affect deeply patients' quality of life (QoL).2 Home me-
chanical ventilation (HMV) is a well-established treatment 
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Abstract
Introduction: Chronic respiratory insufficiency impacts patients' lives and reduces 
quality of life. The Severe Respiratory Insufficiency (SRI) questionnaire examines 
health-related quality of life and is designed specifically for patients receiving home 
mechanical ventilation (HMV) for chronic respiratory failure (CRF).
Objectives: The aim of this study was to validate the Finnish version of the SRI and 
study its reproducibility in patients with CRF.
Methods: Our 74 patients receiving HMV or long-term oxygen treatment for CRF 
or both completed the SRI and St George's Respiratory questionnaires (SGRQ) three 
times (at baseline, and then one week and one month later). Reliability and validity 
of the questionnaires was analysed with Cronbach's alpha and intraclass correlation 
coefficient. Patients were prospectively followed up for 5 years, with data collected 
on their use of hospital services and mortality.
Results: Cronbach's alpha in the SRI ranged from 0.67 to 0.88 and was >0.7 on all 
subscales except the “attendant symptoms and sleep”. On four subscales, Cronbach’s 
alpha was >0.8, and on the summary scale, 0.95. The SRI showed high correlation 
with SGRQ. Both tests showed good reproducibility. During the 5-year follow-up, 
27 (36%) patients died.
Conclusions: The Finnish SRI proved valid, reliable and reproducible. Its psycho-
metric properties were good and similar to those of the original questionnaire and of 
other validation studies.
K E Y W O R D S
chronic respiratory failure (CRF), Finland, health-related quality of life (HRQL), severe respiratory 
insufficiency questionnaire (SRI), validation
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for CRF. It may be delivered either by non-invasive (NIV) or 
by invasive mechanical ventilation. Long-term oxygen treat-
ment (LTOT) is used for hypoxemic CRF patients, alone or 
combined with HMV.
To assess the impact of a chronic disease and its treat-
ment on patients’ lives, health-related quality-of-life 
(HRQL) questionnaires are important instruments. Many 
are generic, like the MOS 36-Item Short-Form Health 
Survey (SF-36), and allow comparison of HRQL between 
different diseases. They may not be able to detect changes 
in QoL in a specific disease, however. CRF patients treated 
with NIV or LTOT or both show specific problems—ones 
absent in generic or even respiratory-specific HRQL ques-
tionnaires. Assessment of their HRQL therefore requires a 
more explicit questionnaire.
The severe respiratory insufficiency questionnaire (SRI) 
and Maugeri respiratory failure questionnaire (MRF) are 
HRQL questionnaires specifically designed for patients with 
CRF who are receiving HMV. The SRI is multidimensional 
HRQL questionnaire with good psychometric properties.3 
It has proven valid, reliable and sensitive to changes, and—
when compared to other questionnaires (eg, MFR, SGRQ)—
it has scored the best.4-6 The MRF is faster to complete, but it 
lacks a psychological domain and measures mainly patients’ 
activity and level of health. The SRI has been translated and 
validated in many countries including Spain,7,8 the United 
Kingdom,9 Norway,10 Portugal,11 Japan,12 and China,13 In 
Germany14 and in China,15 the SRI has also been validated 
in LTOT users.
The aim of this study was to validate the Finnish SRI in 
patients who are using HMV for CRF, also including patients 
using LTOT alone or combined with HMV. We followed up 
the patients for 5 years, to be able also to assess their 5-year 
mortality.
2 |  MATERIALS AND METHODS
2.1 | Patients and study design
Patients with CRF treated with HMV or LTOT or with both, 
having a follow-up visit in the Peijas or Meilahti Hospitals 
pulmonary outpatient clinic from June 2012 to 2013, re-
ceived invitations to participate in this validation study. 
Patients were excluded if they were undergoing invasive 
ventilation or had obstructive sleep apnea (OSA) treated with 
continuous positive airway pressure (CPAP). All patients had 
to be clinically stable, without any exacerbations in the pre-
ceding 3 months, and treated with HMV or LTOT or with 
both for at least three months before entering the study. Their 
respiratory failure may be attributed to various diseases. In 
addition, some patients had OSA treated with NIV due to 
severe hypoxemia without hypercapnia. Of the 155 patients 
fulfilling our inclusion criteria, 74 (48%) entered the study 
and answered the questionnaires. Each patient signed a writ-
ten consent form. Both the SRI and the SGRQ were mailed 
to the patients at three time points: the first (baseline) be-
tween March and November 2013, and then 1 week and then 
1 month later. The patients also provided basic sociodemo-
graphic data.
Five years later, in 2018, we collected information from 
patient records concerning treatment modality, diagnosis of 
CRF, use of hospital services and mortality data during the 
5-year period. The patients made up six diagnosis groups: 
COPD, OHS, RTWD, NMD, OSA and miscellaneous.
The study took place at the Peijas and Meilahti Hospitals, 
both associated with Helsinki University Hospital (HUH), 
Finland. The medical ethics committee of Helsinki University 
approved the study (study number 370/13/03/01/2012). The 
author of the SRI questionnaire, Wolfram Windisch, gave his 
permission to use this questionnaire.
2.2 | The SRI and SGRQ questionnaires
The SRI is a HRQL questionnaire containing 49 items assess-
ing the patient's physical, social and psychological health. Its 
seven subscales are respiratory complaints (RC), physical 
functioning (PF), attendant symptoms and sleep (AS), social 
relationships (SR), anxiety (AX), psychological well-being 
(WB) and social functioning (SF). The summary scale (SS) 
is the average of the subscale scores. Each item is scored on a 
5-point Likert scale. All subscales and the SRI-SS range from 
0 to 100, a higher score indicating a better QoL.3
The SGRQ is a frequently used respiratory-specific HRQL 
questionnaire validated for various respiratory diseases (eg, 
COPD, asthma16-18). The SGRQ has not been validated in 
 patients receiving HMV or LTOT or both for CRF. It com-
prises three subscales: symptoms, activity and impacts, and 
a total score calculated from these subscales. In the SGRQ, 
the scale is also 0-100, but 100 represents the poorest and 0 
the best QoL. Due to this difference, the SGRQ results were 
modified so that these two scales are comparable to each 
other and in the analysis 100 represents the best QoL.
2.3 | Translation of the Finnish SRI
The SRI questionnaire was first translated from German into 
Finnish by a professional translator utilizing medical glos-
saries and parallel texts. The source text and the translation 
were then forwarded to a German-speaking medical profes-
sional (Bachelor of Medicine) who revised the translation 
particularly in regard to its medical terminology. The final 
terminological and translation decisions depended on the col-
laboration of both parties. Lastly, an independent third-party 
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translator reviewed the equivalence between the original and 
the translation in order to guarantee the validity of the pro-
cess and the Finnish version of the SRI questionnaire.
2.4 | Statistical analysis
Statistical analysis was by SPSS, version 24 (IBM SPSS 
Statistics). We considered P values  <  0.05 statistically sig-
nificant. Diagnostic groups’ comparison was by t-test and 
ANOVA. Reliability calculation involved analysis of internal 
consistency with Cronbach's alpha in the subscales and the 
SRI-SS. Cronbach's alpha 0.7-0.79 was considered as accept-
able, 0.8-0.89 as good and >0.9 as excellent. Validity came 
from a comparison of the Finnish SRI to the Finnish SGRQ. 
Spearman's correlation coefficient served for calculating cor-
relations between the SRI and SGRQ. Analysis of reproduci-
bility of the SRI utilized the Intraclass Correlation Coefficient. 
The number of patients varies slightly in the analyses, because 
if a patient left even one question unanswered, the SPSS ex-
cluded this patients' questionnaire. Test scores were calculated 
as averages, and because of the relatively small patient cohort, 
also as percentiles. We analysed the difference in HRQL be-
tween patients who died and survived and its association with 
5-year mortality with the independent samples t-test.
3 |  RESULTS
3.1 | Patient characteristics
Among their characteristics, 74 patients’ mean average smok-
ing amount was 27 pack years (Table  1). Between January 
2013 and March 2018, each patient had on average 3.8 (SD 
2.7, maximum 13) follow-up visits in the pulmonology outpa-
tient clinic, and 2.5 (SD 3.4, maximum 22) episodes of care in 
the pulmonology ward. In total, these patients had 285 visits 
to the outpatient clinic and 183 episodes of care in the ward.
3.2 | Differences between diseases in HRQL
The SRI-SS for all patients was 59.3  ±  16.8 (Figure  1 
and Table S1). In the Finnish SRI, HRQL was best in the 
OSA group (71.8  ±  14.5), second best in the NMD group 
(64.4 ± 11.7), and poorest in the COPD (55.3 ± 14.6) and 
miscellaneous (55.4 ± 29.2) groups.
The highest SRI scores were on the SR subscale for all but 
the OHS, NMD and miscellaneous groups. The lowest scores 
were for PF, except for the OSA group, which had the lowest 
score for the AX (Figure 1).
The difference was statistically significant between NMD 
and COPD patients on the RC subscale (P = .002), and on 
the PF subscale between COPD and OSA (P = .003), OHS 
and OSA (P = .040), and NMD and OSA (P = .041). SGRQ 
scores were similarly distributed among all patient groups 
(Tables S2 and S3).
3.3 | Reliability and validity of SRI, and 
reproducibility of SRI and SGRG
Cronbach's alpha ranged on the SRI subscales between 
0.67 and 0.89 and was >0.7 on all subscales except the AS 
(Table 2). The SRI-SS was 0.95. These results demonstrated 
high internal consistency.
T A B L E  1  Patients' characteristics
N(%) COPD RCWD NMD OHS OSA Misca Total
Patients 28 (38) 7 (9) 12 (16) 15 (20) 7 (9) 5 (7) 74 (100%)
Men 21 (75) 2 (33) 5 (42) 8 (53) 4 (57) 0 40 (54)
Age (mean ± SD) 71 ± 6.3 64 ± 14.4 59 ± 14.0 64 ± 8.1 64 ± 7.0 67 ± 18.2 66 ± 10.7
5-y mortality 18 (64) 1 (14) 3 (25) 2 (13) 0 3 (60) 27 (36)
Smokingb : Current/
Ex-smoker/
never-smoker
5/21/2 0/2/4 0/7/4 1/9/5 1/4/1 0/2/3 7(10)/45(63)/19(27)
NIV 7 (25) 6 (86) 9 (82) 10 (67) 6 (86) 1 (20) 39 (53)
LTOT 8 (29) 0 0 0 0 3 (60) 11 (15)
LTOT and NIV 12 (43) 1 (14) 1 (9) 4 (27) 1 (14) 1 (20) 20 (27)
Treatment cessationc 1 (4) 0 1 (9) 1 (7) 0 0 3 (4)
Abbreviations: COPD, chronic obstructive pulmonary disease; LTOT, long-term oxygen treatment; Misc, miscellaneous; NIV, non-invasive ventilation; NMD, 
neuromuscular disease; OHS, obesity hypoventilation syndrome; OSA, obstructive sleep apnea; RCWD, restrictive thoracic wall disease.
aThree had pulmonary hypertension, one obliterative bronchiolitis and severe asthma, and one status post-pulmonary embolism. 
bSmoking information missing for three patients. 
cDuring the 5-year follow-up. 
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The correlation matrix between SRI and SGRQ is pre-
sented in Table 3. Correlations between the two questionnaires 
and their subscales were high, with the highest correlation 
between SRI-RC and SGRQ total (0.84, P < .001); RC also 
had a very high correlation with all the SGRQ subscales. The 
correlation was good between the SRI-SS and the SGRQ 
impacts (0.80, P < .001), even better than correlation of the 
SRI-SS and SGRQ total (0.75, P < .001). The SRI AX had 
a good correlation with SGRQ impacts (0.74, P < .001) and 
with total score (0.73, P < .001). Those subscales targeting 
the same aspects of life were generally well comparable; the 
lowest correlation was between SR and SGRQ activity (0.19, 
P = .132), which measures very different aspects.
The reproducibility of SRI and SGRQ results between the 
three different assessments was also high (Table 4).
Comparison of the HRQL between those patients who 
died during the follow-up and those who survived showed 
statistically significant differences in the SRI-SS, RC, SR 
and SF; a lower score in these subscales was associated with 
increased mortality (Figure 2). Moreover, patients who died 
had undergone more treatment episodes in the pulmonary 
ward (P = .007), but fewer visits in the pulmonary outpatient 
clinic (P = .032).
4 |  DISCUSSION
The HRQL of patients with CRF is severely diminished. 
Thus far, we have lacked any specific HRQL questionnaire 
for CRF patients receiving HMV or LTOT or both in Finland. 
Our study showed that the Finnish SRI had high psychometric 
properties and good reliability and validity. Reproducibility 
of both the SRI and the SGRG was good among three differ-
ent assessments occurring during 1 month.
Reliability was analysed with internal consistency using 
Cronbach's alpha. Cronbach's alpha was over 0.7 in all sub-
scales, except in the AS, and the SRI-SS was 0.95. In the 
original German SRI, the Cronbach's alpha was 0.73-0.79 on 
three subscales, 0.80 to 0.89 on four subscales, and SRI-SS 
was 0.89.3 Our results were similar to this original SRI and 
to other SRI validations. In the Spanish SRI, the SRI-SS was 
0.938; in the English one, 0.939; in the Norwegian, 0.9410; in 
F I G U R E  1  Average scores and standard deviations for SRI (0 week). The statistically significant differences bolded. P is < 0.05 when there 
exists a statistically significant difference between the scores of two or more diagnosis groups. COPD, chronic obstructive pulmonary disease; 
Misc, miscellaneous; NMD, neuromuscular disease; OHS, obesity hypoventilation syndrome; OSA, obstructive sleep apnea; RCWD, restrictive 
thoracic wall disease; SRI, severe respiratory insufficiency questionnaire; SRI-SS, summary scale; SRI-RC, respiratory complaints; SRI-PF, 
physical functioning; SRI-AS, attendant symptoms and sleep; SRI-SR, social relationships; SRI-AX, anxiety; SRI-WB, psychological well-being; 
SRISF, social functioning
ϬϮϬ
ϰϬϲϬ
ϴϬϭϬϬ
ϭϮϬ
SRI-SS SRI-RC SRI-PF SRI-AS SRI-SR SRI-AX SRI-WB SRI-SF
COPD RCWD NMD OHS OSA Misc Total
p=0.013 p=0.776 p=0.331 p=0.882 p=0.445 p=0.219p=0.224 p=0.002
T A B L E  2  Reliability of the subscales of the Finnish severe 
respiratory insufficiency questionnaire
  Number of items Cronbach's α
Respiratory complaints (RC) 8 0.80
Physical functioning (PF) 6 0.72
Attendant symptoms and 
sleep (AS)
7 0.67
Social relationships (SR) 6 0.76
Anxiety (AX) 5 0.81
Psychological well-being 
(WB)
9 0.89
Social functioning (SF) 8 0.84
Summary scale (SS) 49 0.95
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the Portuguese, 0.8411; in the Japanese, 0.9212; in the Chinese, 
0.94-0.9513,15; and in the German version comparing LTOT 
and NIV, 0.90.14 In our study, the AS subscale scored the low-
est (0.67), similar to the Chinese,13 Norwegian10 and German14 
versions. If question 9 were excluded from the Finnish version, 
the Cronbach's alpha in AS would rise to 0.73, indicating that 
the question might be measuring a slightly different aspect 
then the other questions on that subscale measured. Question 
9 asks about the person's ability to fall asleep, while the other 
questions on the subscale inquire about daily symptoms or 
sleep quality. The reliability of the Finnish version was good, 
and similar to or even stronger than the original German SRI.
We compared the SRI with the SGRQ. To our knowledge, 
all other SRI validations have compared the SRI to SF-36. 
SGRQ is a widely used HRQL questionnaire validated for 
many respiratory diseases, but not validated in patients re-
ceiving HMV. The best correlation was between SRI RC (re-
spiratory complaints) and SGRQ total. The RC had a good 
correlation with all the SGRQ subscales, as well. The SRI 
summary scale and the SGRQ impacts subscale correlated 
well also, even better than did the SRI-SS and the total 
SGRQ. This indicates that the SGRQ concentrates more on 
the respiratory symptoms, whereas the SRI measures more 
broadly the physical and mental health factors. Overall, the 
subscales that targeted comparable aspects of life showed 
good correlations with each other.
SRI-SS scores were similar to the other validations, 
where the results ranged from 52.93 (SD 15.11) to 59.4 
(SD 20.2)9-13,15 even though the patient-group distributions 
differed from those of the other SRI validations. In many 
validations, COPD patients have been the only or the largest 
group, which largely explains the similar results. The SGRQ 
and SRI scores were comparable to each other. The SGRQ 
finding of our COPD group is also in line with findings of 
other studies with GOLD stage-IV patients.19,20
In our study, 5-year mortality was 36% and was even 
higher (over 60%) in the COPD and miscellaneous groups. In 
other studies on COPD patients' mortality, mortality during 
3-7 years ranged from 19.5% to 33%.21-24 In studies which 
included patients with CRF due to different pathologies, the 
mortality was 19%-58% during 4-11 years.25,26 Compared to 
these studies’ findings, the mortality rate in our COPD pa-
tients was higher, and in the RCWD, NMDand OHS groups, 
lower. This imbalance is probably due to our small patient 
cohorts, and shows also how severely ill our COPD patients 
treated with HMV were.
The HRQL questionnaires can also be useful for assess-
ing their discriminative property (to distinguish patients with 
  SGRQ symptoms SGRQ activity SGRQ impacts SGRQ total
SRI-RC 0.67 0.61 0.80 0.84
SRI-PF 0.29 0.55 0.63 0.64
SRI-AS 0.34 0.28 0.51 0.42
SRI-SR 0.42 0.19* 0.46 0.40
SRI-AX 0.59 0.58 0.74 0.73
SRI-WB 0.44 0.31 0.51 0.48
SRI-SF 0.42 0.43 0.63 0.58
SRI-SS 0.62 0.53 0.80 0.76
Note: The highest correlations in bold. 
Abbreviations: SGRQ, St George's respiratory questionnaire; SRI, severe respiratory insufficiency 
questionnaire; SRI-AS, attendant symptoms and sleep; SRI-AX, anxiety; SRI-PF, physical functioning; 
SRI-RC, respiratory complaints; SRI-SF, social functioning; SRI-SR, social relationships; SRI-SS, summary 
scale; SRI-WB, psychological well-being.
*In all the result, P < .05, except the one marked *, where P = .132.
T A B L E  3  Correlation matrix between 
the SRI and SGRQ (Spearman's correlation)
T A B L E  4  Reproducibility calculated with intraclass correlation 
coefficient (ICC) from SRI and SGRQ 0 week, 1 week and 1 month
  ICC
95% 
Confidence 
interval
SRI-RC (N = 48) 0.95 0.92-0.97
SRI-PF (N = 48) 0.96 0.94-0.98
SRI-AS (N = 48) 0.93 0.88-0.96
SRI-SR (N = 48) 0.95 0.92-0.97
SRI-AX (N = 48) 0.93 0.89-0.96
SRI-WB (N = 48) 0.94 0.91-0.97
SRI-SF (N = 48) 0.95 0.92-0.97
SRI-SS (N = 48) 0.97 0.96-0.98
SGRQ symptoms (N = 45) 0.90 0.84-0.94
SGRQ activity (N = 38) 0.96 0.92-0.98
SGRQ impact (N = 43) 0.96 0.93-0.98
SGRC total (N = 35) 0.97 0.95-0.98
Abbreviations: SGRQ, St George's respiratory questionnaire; SRI, severe 
respiratory insufficiency questionnaire; SRI-AS, attendant symptoms and 
sleep; SRI-AX, anxiety; SRI-PF, physical functioning; SRI-RC, respiratory 
complaints; SRI-SF, social functioning; SRI-SR, social relationships; SRI-SS, 
summary scale; SRI-WB, psychological well-being.
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better from those with worse HRQL), their responsive prop-
erty (measures how the HRQL changes with treatment inter-
vention or over time) and their predictive property (to predict 
future outcomes, eg, mortality).27 In recent studies, results for 
SRI, MRF and SGRQ were strong predictors of mortality in 
COPD patients, independently of pulmonary function, BMI or 
hypercapnia.21-22,25,27 In our study, results for the SRI-SS and 
subscales RC, SR and SF were associated with patients' prog-
nosis during the following 5 years: patients who at baseline 
had lower scores on these subscales and on SRI-SS showed 
lower HRQL and were more likely to die during the following 
5 years. Comparing the patients who survived to those who 
died, those who died had more treatment episodes in the pul-
monary ward, but fewer visits in the outpatient clinic. It is logi-
cal that those who died, with lower HRQL, were in the poorest 
condition and needed more treatment in the pulmonary ward. 
Another reason for the lower number of outpatient clinic visits 
is that in HUH the weakest patients often have their follow-up 
visits in pulmonary wards. However, as the study was neither 
aimed to nor designed to analyse CRF patients’ prognosis, the 
findings as regards mortality are at best only indicative.
There are some limitations to our study. Our number of 
patients was relatively small (74 patients in total), which rep-
resents only a portion of our CRF patients treated with HMV 
or LTOT or both at that time. In other validation studies, the 
number of patients has ranged from 56 to 152.
Only 48% of the patients invited to participate were 
willing to enter the study, even though their participation 
required neither major physical effort nor extra hospital visits. 
However, answering the long questionnaires was quite labo-
rious. We also assume that this patient group's weak overall 
condition limited the number of participants. The most com-
mon pathologies for CRF were included, and the results were 
in line with those of the other validations. For validation of 
the SRI, the patient number can thus be considered to have 
been sufficient.
A strength of this study was that the reproducibility of 
both the SRI and SGRQ was also analysed, and found to 
be good. To our knowledge, reproducibility of SRI has un-
dergone study earlier only in the Spanish validation,8 and 
showed comparable results. Reproducibility of SGRG has 
been affirmed to be good.28
In conclusion, we showed that the Finnish version of the 
SRI was valid, reliable and reproducible. Its psychometric 
properties are in line with those of the original German ques-
tionnaire and other validation studies. The Finnish SRI qual-
ifies for use in assessing the HRQL in CRF patients treated 
with HMV or LTOT or both.
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F I G U R E  2  Mortality vs HRQL (SRI 0 week) analysed with independent samples t-test. The statistically significant differences bolded. 
HRQL, health-related quality of life, SRI-SS, summary scale; SRI-RC, respiratory complaints; SRI-PF, physical functioning; SRI-AS, attendant 
symptoms and sleep; SRI-SR, social relationships; SRI-AX, anxiety; SRI-WB, psychological well-being; SRI-SF, social functioning
ϬϭϬϮϬ
ϯϬϰϬϱϬ
ϲϬϳϬϴϬ
ϵϬϭϬϬ
SRI-SS SRI-RC SRI-PF SRI-AS SRI-SR SRI-AX SRI-WB SRI-SF
Mean scores and standard deviation of the living
Mean scores and standard deviation of the deceased
p=0.009 p=0.003 p=0.129 p=0.211 p=0.018 p=0.148 p=0.167 p=0.002
   | 7KOTANEN ET Al.
AUTHOR CONTRIBUTIONS
All authors read and approved the final manuscript. P. 
Kotanen takes responsibility of the whole work.
Study design: Kainu, Kreivi
Data collection: Kainu
Translation of the questionnaires: Lehtomäki
Data analysis: Kotanen, Bergman
Written report: Kotanen, Brander, Kreivi
ETHICS
The medical ethics committee of Helsinki University ap-
proved the study (study number 370/13/03/01/2012).
ORCID
Petra Kotanen   https://orcid.org/0000-0002-0470-2582 
Annette Kainu   https://orcid.org/0000-0001-6847-4358 
Paula Bergman   https://orcid.org/0000-0003-4672-2554 
Hanna-Riikka Kreivi   https://orcid.
org/0000-0002-9361-8322 
REFERENCES
 1. Simonds AK. Home mechanical ventilation: an overview. Ann Am 
Thorac Soc. 2016;13(11):2035-2044.
 2. Windisch W. Impact of home mechanical ventilation on health-re-
lated quality of life. Eur Respir J. 2008;32(5):1328-1336.
 3. Windisch W, Freidel K, Schucher B, et al. The severe respiratory 
insufficiency (SRI) questionnaire a specific measure of health-re-
lated quality of life in patients receiving home mechanical ventila-
tion. J Clin Epidemiol. 2003;56(8):752-759.
 4. Oga T, Taniguchi H, Kita H, et al. Comparison of different dis-
ease-specific health-related quality of life measurements in pa-
tients with long-term noninvasive ventilation. Can Respir J. 
2017;2017:1-7.
 5. Windisch W, Budweiser S, Heinemann F, Pfeifer M, Rzehak P. The 
severe respiratory insufficiency questionnaire was valid for COPD 
patients with severe chronic respiratory failure. J Clin Epidemiol. 
2008;61(8):848-853.
 6. Struik FM, Kerstjens HAM, Bladder G, et al. The severe respira-
tory insufficiency questionnaire scored best in the assessment of 
health-related quality of life in chronic obstructive pulmonary dis-
ease. J Clin Epidemiol. 2013;66(10):1166-1174.
 7. López-Campos JL, Failde I, Jiménez AL, et al. Health-related 
quality of life of patients receiving home may mechanical 
ventilation: the Spanish version of the severe respiratory in-
sufficiency questionnaire. Arch Bronconeumol (English Ed). 
2006;42(11):588-593.
 8. López-Campos JL, Failde I, Masa JF, et al. Transculturally 
adapted Spanish SRI questionnaire for home mechanically ven-
tilated patients was viable, valid, and reliable. J Clin Epidemiol. 
2008;61(10):1061-1066.
 9. Ghosh D, Rzehak P, Elliott MW, Windisch W. Validation of the 
English severe respiratory insufficiency questionnaire. Eur Respir 
J. 2012;40(2):408-415.
 10. Markussen H, Lehmann S, Nilsen RM, Natvig GK. The Norwegian 
version of the severe respiratory insufficiency questionnaire. Int J 
Nurs Pract. 2015;21(3):229-238.
 11. Ribeiro C, Ferreira D, Conde S, Oliveira P, Windisch W. Validation 
of the portuguese severe respiratory insufficiency questionnaire 
for home mechanically ventilated patients. Rev Port Pneumol. 
2017;23(3):139-145.
 12. Oga T, Taniguchi H, Kita H, et al. Validation of the Japanese 
severe respiratory insufficiency questionnaire in hypercap-
nic patients with noninvasive ventilation. Respir Investig. 
2017;55(2):166-172.
 13. Chen R, Guan L, Wu W, et al. The Chinese version of the se-
vere respiratory insufficiency questionnaire for patients with 
chronic hypercapnic chronic obstructive pulmonary disease re-
ceiving non-invasive positive pressure ventilation. BMJ Open. 
2017;7(8):e017712.
 14. Walterspacher S, July J, Kohlhaufl M, Rzehak P, Windisch 
W. The severe respiratory insufficiency questionnaire for sub-
jects with COPD with long-term oxygen therapy. Respir Care. 
2016;61(9):1186-1191.
 15. Guan L, Xu J, Wu W, et al. Chinese version of the severe respi-
ratory insufficiency questionnaire for patients with COPD receiv-
ing long-term oxygen therapy. Int J Chron Obstruct Pulmon Dis. 
2018;13:1537-1543.
 16. Jones PW, Quirk FH, Baveystock CM. The St George's respiratory 
questionnaire. Respir Med. 1991;85:25-31.
 17. Nelsen LM, Vernon M, Ortega H, et al. Evaluation of the psycho-
metric properties of the St George's respiratory questionnaire in 
patients with severe asthma. Respir Med. 2017;128:42-49.
 18. Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychomet-
ric properties of the St George's respiratory questionnaire (SGRQ) 
in patients with idiopathic pulmonary fibrosis: a literature review. 
Health Qual Life Outcomes. 2014;12:124.
 19. Ong KC, Lu SJ, Soh CSC. Does the multidimensional grad-
ing system (BODE) correspond to differences in health status 
of patients with COPD? Int J Chron Obstruct Pulmon Dis. 
2006;1(1):91-96.
 20. Jones PW, Brusselle G, Dal Negro RW, et al. Health-related quality 
of life in patients by COPD severity within primary care in Europe. 
Respir Med. 2011;105(1):57-66.
 21. Oga T, Taniguchi H, Kita H, et al. Analysis of the relationship 
between health status and mortality in hypercapnic patients with 
noninvasive ventilation. Clin Respir J. 2017;11(6):772-780.
 22. Carone M, Antoniu S, Baiardi P, Digilio VS, Jones P, Bertolotti 
G. Predictors of mortality in patients with COPD and chronic 
respiratory failure: the quality-of-life evaluation and survival 
study (QuESS): a three-year study. J Chronic Obstr Pulm Dis. 
2016;13(2):130-138.
 23. Oga T, Nishimura K, Tsukino M, et al. Health status measured 
with the CRQ does not predict mortality in COPD. Eur Respir J. 
2002;20(5):1147-1151.
 24. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related 
quality of life and mortality in male patients with chronic obstruc-
tive pulmonary disease. Am J Respir Crit Care Med. 2002;166(5): 
680-685.
 25. Budweiser S, Hitzl AP, Jörres RA, Schmidbauer K, Heinemann F, 
Pfeifer M. Health-related quality of life and long-term prognosis 
in chronic hypercapnic respiratory failure: a prospective survival 
analysis. Respir Res. 2007;8:1-9.
 26. Keskes N, Boussoffara L, Khalil H, Adhieb A, Ouaja R, Knani J. 
Predictive factors of mortality in patients with chronic respiratory 
failure. Eur Respir J. 2016;48(suppl 60):PA731.
8 |   KOTANEN ET Al.
 27. Oga T, Windisch W, Handa T, Hirai T, Chin K. Health-related 
quality of life measurement in patients with chronic respiratory 
failure. Respir Investig. 2018;56:214-221.
 28. Weldam SWM, Schuurmans MJ, Liu R, Lammers J-WJ. Evaluation 
of Quality of Life instruments for use in COPD care and research: 
A systematic review. Int J Nurs Stud. 2013;50:688-707.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in 
the Supporting Information section.
How to cite this article: Kotanen P, Kainu A, 
Brander P, Bergman P, Lehtomäki A, Kreivi H-R. 
Validation of the Finnish severe respiratory 
insufficiency questionnaire. Clin Respir J. 2020;00: 
1–8. https://doi.org/10.1111/crj.13181
